Literature DB >> 34921329

Biosynthesis of a novel ganoderic acid by expressing CYP genes from Ganoderma lucidum in Saccharomyces cerevisiae.

Wen-Fang Wang1,2, Han Xiao3, Jian-Jiang Zhong4.   

Abstract

Ganoderic acids (GAs), a group of highly oxygenated lanostane-type triterpenoids from the traditional Chinese medicinal mushroom Ganoderma lucidum, possessed significant pharmacological activities. Due to the difficulty in its genetic manipulation, low yield, and slow growth of G. lucidum, biosynthesis of GAs in a heterologous host is a promising alternative for their efficient production. Heterologous production of a GA, 3-hydroxy-lanosta-8,24-dien-26-oic acid (HLDOA), was recently achieved by expressing CYP5150L8 from Ganoderma lucidum in Saccharomyces cerevisiae, but post-modification of HLDOA to biosynthesize other GAs remains unclear. In this study, another P450 from G. lucidum, CYP5139G1, was identified to be responsible for C-28 oxidation of HLDOA, resulting in the formation of a new GA 3,28-dihydroxy-lanosta-8,24-dien-26-oic acid (DHLDOA) by the engineered yeast, whose chemical structure was confirmed by UPLC-APCI-HRMS and NMR. In vitro enzymatic experiments confirmed the oxidation of HLDOA to DHLDOA by CYP5139G1. As the DHLDOA production was low (0.27 mg/L), to improve it, the strategy of adjusting the dosage of hygromycin and geneticin G418 to respectively manipulate the copy number of plasmids pRS425-Hyg-CYP5150L8-iGLCPR (harboring CYP5150L8, iGLCPR, and hygromycin-resistant gene hygR) and pRS426-KanMx-CYP5139G1 (harboring CYP5139G1 and G418-resistant gene KanMx) was adopted. Finally, 2.2 mg/L of DHLDOA was obtained, which was 8.2 fold of the control (without antibiotics addition). The work enriches the GA biosynthetic enzyme library, and is helpful to construct heterologous cell factories for other GA production as well as to elucidate the authentic GA biosynthetic pathway in G. lucidum. KEY POINTS: • Another P450 gene responsible for GA's post-modification was discovered and identified. • One new GA, DHLDOA, was identified and produced via engineered yeast. • With the balance of the two CYP genes expression, DHLDOA production was significantly improved.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cytochrome P450 (CYP); Ganoderma lucidum; Saccharomyces cerevisiae; Synthetic biology; Triterpenoid

Mesh:

Substances:

Year:  2021        PMID: 34921329     DOI: 10.1007/s00253-021-11717-w

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  40 in total

1.  Secondary metabolites from Ganoderma.

Authors:  Sabulal Baby; Anil John Johnson; Balaji Govindan
Journal:  Phytochemistry       Date:  2015-05-11       Impact factor: 4.072

2.  Use of expression-enhancing terminators in Saccharomyces cerevisiae to increase mRNA half-life and improve gene expression control for metabolic engineering applications.

Authors:  Kathleen A Curran; Ashty S Karim; Akash Gupta; Hal S Alper
Journal:  Metab Eng       Date:  2013-07-12       Impact factor: 9.783

Review 3.  From 2000years of Ganoderma lucidum to recent developments in nutraceuticals.

Authors:  Karen S Bishop; Chi H J Kao; Yuanye Xu; Marcus P Glucina; R Russell M Paterson; Lynnette R Ferguson
Journal:  Phytochemistry       Date:  2015-03-17       Impact factor: 4.072

4.  Homology-integrated CRISPR-Cas (HI-CRISPR) system for one-step multigene disruption in Saccharomyces cerevisiae.

Authors:  Zehua Bao; Han Xiao; Jing Liang; Lu Zhang; Xiong Xiong; Ning Sun; Tong Si; Huimin Zhao
Journal:  ACS Synth Biol       Date:  2014-09-19       Impact factor: 5.110

5.  Protein-protein and protein-membrane associations in the lignin pathway.

Authors:  Jean-Etienne Bassard; Ludovic Richert; Jan Geerinck; Hugues Renault; Frédéric Duval; Pascaline Ullmann; Martine Schmitt; Etienne Meyer; Jerôme Mutterer; Wout Boerjan; Geert De Jaeger; Yves Mely; Alain Goossens; Danièle Werck-Reichhart
Journal:  Plant Cell       Date:  2012-11-21       Impact factor: 11.277

6.  Production of miltiradiene by metabolically engineered Saccharomyces cerevisiae.

Authors:  Zhubo Dai; Yi Liu; Luqi Huang; Xueli Zhang
Journal:  Biotechnol Bioeng       Date:  2012-05-17       Impact factor: 4.530

7.  Customized optimization of metabolic pathways by combinatorial transcriptional engineering.

Authors:  Jing Du; Yongbo Yuan; Tong Si; Jiazhang Lian; Huimin Zhao
Journal:  Nucleic Acids Res       Date:  2012-06-19       Impact factor: 16.971

8.  Genome sequence of the model medicinal mushroom Ganoderma lucidum.

Authors:  Shilin Chen; Jiang Xu; Chang Liu; Yingjie Zhu; David R Nelson; Shiguo Zhou; Chunfang Li; Lizhi Wang; Xu Guo; Yongzhen Sun; Hongmei Luo; Ying Li; Jingyuan Song; Bernard Henrissat; Anthony Levasseur; Jun Qian; Jianqin Li; Xiang Luo; Linchun Shi; Liu He; Li Xiang; Xiaolan Xu; Yunyun Niu; Qiushi Li; Mira V Han; Haixia Yan; Jin Zhang; Haimei Chen; Aiping Lv; Zhen Wang; Mingzhu Liu; David C Schwartz; Chao Sun
Journal:  Nat Commun       Date:  2012-06-26       Impact factor: 14.919

Review 9.  Synthetic biology strategies for microbial biosynthesis of plant natural products.

Authors:  Aaron Cravens; James Payne; Christina D Smolke
Journal:  Nat Commun       Date:  2019-05-13       Impact factor: 14.919

10.  Anticancer Activity of Ganoderic Acid DM: Current Status and Future Perspective.

Authors:  John Matthew Bryant; Mollie Bouchard; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2017-12-12
View more
  2 in total

Review 1.  Synthetic Biology Tools for Engineering Microbial Cells to Fight Superbugs.

Authors:  Angel León-Buitimea; Francisco de Jesús Balderas-Cisneros; César Rodolfo Garza-Cárdenas; Javier Alberto Garza-Cervantes; José Rubén Morones-Ramírez
Journal:  Front Bioeng Biotechnol       Date:  2022-05-04

2.  Tetra-, penta-, and hexa-nor-lanostane triterpenes from the medicinal fungus Ganoderma australe.

Authors:  Lin Zhou; Subiy Akbar; Meng-Xi Wang; He-Ping Chen; Ji-Kai Liu
Journal:  Nat Prod Bioprospect       Date:  2022-08-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.